ROIV
Roivant Sciences Ltd.
There isn't enough reported data to score ROIV yet.
ROIV Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Strong |
ROIV's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
ROIV PE Valuation
ROIV has no meaningful PE right now: it lost money over the past year.
ROIV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ROIV's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
ROIV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.57 | -$0.02 |
| Q2 2026 | -$0.47 | +$0.22 |
| Q1 2026 | -$0.54 | -$0.30 |
| Q4 2025 | -$1.16 | -$1.02 |
| Q3 2025 | -$0.55 | -110% |
| Q2 2025 | -$0.69 | -112% |
| Q1 2025 | -$0.24 | -105% |
| Q4 2024 | -$0.14 | -103% |
ROIV is still losing money, but far less than before: $0.57 per share over the past year, against $1.55 at its worst in late 2022.
ROIV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +2136% |
| Q2 2026 | $1.4M | -34% |
| Q1 2026 | $2.5M | -67% |
| Q4 2025 | $2M | -78% |
| Q3 2025 | $1.6M | -65% |
| Q2 2025 | $2.2M | -96% |
| Q1 2025 | $7.6M | -74% |
| Q4 2024 | $9M | -76% |
ROIV's revenue is recovering but still below its 2024 peak: $35M last quarter, up 2136% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -763% | +18730 points |
| Q2 2026 | -25381% | -12251 points |
| Q1 2026 | 16478% | +20242 points |
| Q4 2025 | -16966% | -13924 points |
| Q3 2025 | -19493% | -11857 points |
| Q2 2025 | -13130% | -12912 points |
| Q1 2025 | -3764% | -2845 points |
| Q4 2024 | -3043% | -16669 points |
ROIV's operating margin was −763% last quarter, up 18730 points from the same quarter a year ago.
ROIV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $594.2M | +$787.7M |
| Q2 2026 | -$270.9M | -$62.5M |
| Q1 2026 | -$165.1M | +$8.3M |
| Q4 2025 | -$191.5M | +$17.5M |
| Q3 2025 | -$193.5M | +$74.3M |
| Q2 2025 | -$208.4M | -$14.6M |
| Q1 2025 | -$173.4M | -$64.6M |
| Q4 2024 | -$209.1M | +$1.7M |
ROIV has burned cash in almost every quarter: −$33M over the past year, against −$784M the year before.
ROIV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -0.5x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -1.4x | Net Cash |
| Q4 2023 | -1.5x | Net Cash |
ROIV has more cash than debt.
ROIV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.8 | Neutral |
| Stochastic | 60.6 | Neutral |
ROIV's weekly RSI is 65 (neutral) and its Stochastic is 61 (neutral).
ROIV PE vs Healthcare Sector
| Metric | ROIV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ROIV has no meaningful PE right now: it lost money over the past year.
ROIV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.6 | 9.3% above |
| 20 week MA | $36.3 | 10% above |
| 50 week MA | $30.6 | 31% above |
| 100 week MA | $21.6 | 85% above |
| 200 week MA | $16.0 | 149% above |
ROIV is in an uptrend: it's above all five of its weekly moving averages, and 149% above its 200-week average.
ROIV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.92 | $10.1 | +1.8% |
| 2021 | $10.1 | $12.0 | +18% |
| 2022 | $12.0 | $7.01 | -41% |
| 2023 | $7.01 | $11.2 | +60% |
| 2024 | $11.2 | $11.8 | +5.1% |
| 2025 | $11.8 | $22.2 | +88% |
| 2026 YTD | $22.2 | $40.0 | +80% |
ROIV has finished higher in five of the last six years, two of them by more than 50%. It's up 80% so far in 2026.